AtaGenix Laboratories
AtaGenix Laboratories
AtaGenix develops antibodies specific for post-translational modifications (PTMs) — phosphorylation, methylation, acetylation, glycosylation, succinylation, and lactylation. These antibodies distinguish the modified form of a protein from the unmodified form, enabling precise detection and quantification of PTM events in signaling, epigenetics, and disease research.
6+
PTM Types Supported
2-Round
Affinity Purification
Free
Antigen Design
pAb / mAb
Both Available
The key challenge in PTM antibody development is specificity: the antibody must recognize the modified residue without cross-reacting with the unmodified form. AtaGenix solves this through two-round affinity purification — first positive selection with the modified peptide, then negative depletion against the unmodified peptide. This ensures only modification-specific antibodies are delivered.
| Modification | Description | Research Relevance |
| Phosphorylation | pSer, pThr, pTyr at specific residues | Signal transduction, kinase activity, cancer biology |
| Methylation | Mono/di/tri-methylation on Lys or Arg | Epigenetics, histone regulation, aging, cancer |
| Acetylation | Lys acetylation by acetyltransferases | Gene expression, histone regulation, metabolism |
| Glycosylation | N-linked, O-linked, C-linked sugar moieties | Protein folding, cell adhesion, immune function |
| Succinylation | Lys succinylation (discovered 2010) | Metabolic regulation, mitochondrial function |
| Lactylation | Histone Lys lactylation (discovered 2019) | Warburg effect, tumor immunity, cell reprogramming |
Free Antigen Design
Just provide the target protein sequence and modification site. We design the optimal modified and unmodified peptide pair, select linker positions to preserve epitope accessibility, and handle peptide synthesis and carrier conjugation — all included in the project.
Two-Round Affinity Purification
First round: positive selection using the modified peptide column to capture PTM-binding antibodies. Second round: negative depletion using the unmodified peptide column to remove cross-reactive antibodies. The result: antibodies that specifically recognize only the modified form.
In-House Peptide Synthesis
Modified peptide synthesis (phospho, methyl, acetyl, crotonyl, succinyl, lactyl) and carrier conjugation (KLH, BSA) are handled entirely in-house. No external peptide vendor coordination needed — faster turnaround and tighter QC control over the entire process.
AtaGenix's PTM antibody service covers the complete pipeline: antigen design (free), modified + unmodified peptide synthesis, carrier protein conjugation (KLH/BSA), animal immunization, and two-round affinity purification to ensure modification-specific recognition. Both polyclonal (6–8 weeks, 3–5 mg purified antibody) and monoclonal (2–3 months, 1–3 clones + 2 mg purified antibody) options are available. Supported modifications: phosphorylation, methylation, acetylation, glycosylation, succinylation, and lactylation.
A 5-stage pipeline from antigen design to modification-specific antibody. The two-round purification at Step 05 is the critical differentiator that ensures PTM specificity.
01
Antigen Design
Modification site analysis
Modified peptide design
Unmodified control peptide
02
Peptide & Conjugation
Modified peptide synthesis
Unmodified peptide synthesis
KLH / BSA conjugation
03
Immunization
Rabbit (pAb) or rat/mouse (mAb)
Modified peptide-KLH immunogen
Titer monitoring by ELISA
04
Screening (mAb) / Bleed (pAb)
mAb: fusion, subclone, ELISA
pAb: final bleed + serum
Modified vs unmodified ELISA
05
Two-Round Purification
Round 1: modified peptide column (+)
Round 2: unmodified peptide column (−)
QC: WB, ELISA, dot blot
Service Options
| Option | Client Provides | Timeline | Deliverables |
| Polyclonal (pAb) | Protein sequence + modification site | 6–8 weeks | Peptides + serum sample + 3–5 mg purified Ab + report |
| Monoclonal (mAb) | Protein sequence + modification site | 2–3 months | Peptides + 1–3 clones + 2 mg purified Ab + report |
Case Highlight — FGFR3 phospho-Y724 polyclonal antibody: modified peptide immunization in rabbit, two-round affinity purification, validated by Western Blot showing clear discrimination between pervanadate-treated (phospho+) and untreated (phospho−) cell lysates.
Related services: Peptide Synthesis for standalone modified peptides. Polyclonal Antibody for standard (non-PTM) protein targets. Anti-Small Molecule for hapten antibodies. Rapid Hybridoma for standard mouse mAb.
What information do I need to provide?
Just the target protein sequence and the specific modification site (e.g., "Human Histone H3 trimethyl-K27" or "FGFR3 phospho-Y724"). AtaGenix designs the optimal modified and unmodified peptide sequences, selects the conjugation strategy, and handles everything from synthesis through antibody delivery — antigen design is free.
How does two-round purification ensure PTM specificity?
After immunization, the serum contains antibodies against both the modified epitope and the carrier protein/backbone sequence. Two-round purification first captures antibodies that bind the modified peptide (positive selection), then removes any that also bind the unmodified peptide (negative depletion). Only antibodies that recognize the modification itself pass through both rounds. This is verified by comparative ELISA and/or dot blot against both peptide forms.
Should I choose polyclonal or monoclonal for PTM detection?
Polyclonal (6–8 weeks, 3–5 mg) is faster and often sufficient for WB, IHC, and IF applications where high signal is more important than absolute reproducibility. Monoclonal (2–3 months, 1–3 clones) provides batch-to-batch consistency, defined epitope, and unlimited supply from the cell line — preferred for quantitative assays, diagnostics, and long-term research programs requiring reproducible reagents.
Can you develop antibodies against newer modifications like lactylation?
Yes. Our peptide synthesis platform supports lactylation (Kla), succinylation (Ksucc), crotonylation (Kcr), and other emerging modifications in addition to the classic phospho/methyl/acetyl set. The two-round purification strategy works identically for any modification type — the principle (positive selection with modified peptide, negative depletion with unmodified peptide) is universal.
PTM antibody specificity is target- and modification-dependent. Two-round purification significantly reduces but may not completely eliminate cross-reactivity in all cases. Validation data (WB, ELISA) included in technical report. Quote-based pricing.
Explore real-world yeast protein expression case studies from AtaGenix. Our Pichia pastoris and Saccharomyces cerevisiae platforms deliver high-yield recombinant proteins with proper folding and glycosylation — supporting enzyme production, diagnostic antigen development, and antibody screening applications.
AtaGenix provides highly specific anti-tauN368 monoclonal antibodies to support Alzheimer’s disease research using the hTau368 transgenic mouse model. These antibodies enable precise detection of truncated tau fragments in Western blot and immunofluorescence experiments, validating tau accumulation, phosphorylation, and associated cognitive deficits in the hippocampus. With exceptional specificity and stability, AtaGenix’s solutions empower researchers to explore tau pathology mechanisms and advance tau-targeted therapeutic development.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
